Khalid El Bairi is the principal investigator of OVANORDEST studies and the founder of The Cancer Biomarkers Working Group, and he is currently pursuing clinical and translational research in medical oncology. He has published many peerreviewed articles in the field of predictive and prognostic cancer biomarkers to improve survival outcomes in several WoS and Medline-indexed journals. His research focuses particularly on biomarkers for digestive and gynecological cancers such as ovarian and colorectal malignancies. He is currently a member of the board of various international scientific societies such as the International Gynecologic Cancer Society (IGCS), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO), and the American Association for Cancer Research (AACR). He is also an editor and reviewer for more than 40 academic journals and a guest editor for several special issues on emergingtopics in gynecological cancers such as platinum-resistant ovarian cancer. He is also highly interested in teaching evidence-based medicine, clinical research methods, and publishing ethics to medical and PhD students and was selected for the 70th Lindau Nobel Laureate Meeting as a young scientist.